News

Ferring Pharmaceuticals, USA has announced the commercial availability of degarelix for injection, a new injectable gonadotropin-releasing hormone receptor antagonist approved by the FDA for the treatment of hormone

Solta Medical, a provider of anti-aging solutions, has opened the Solta Medical Aesthetic Center to advance the company’s new product development, facilitate research on the Thermage and Fraxel

For the fourth quarter ended December 31, 2008, revenue from continuing operations was $21.9 million, against $12.4 million for the same period in 2007, and $19.0 million for

2008 Highlights Record revenues of $7.1 million in the last quarter Cash and cash equivalents totalling $2.4 million Restructured its debentures and received new financing facilities from Desjardins

Under the terms of the share purchase agreement, Antonius Stegmann, co-founder and chief scientific officer (CSO) of Virosome Biologicals, will remain CSO of Virosome Biologicals. The acquisition of

According to SyntheMed, Repel-CV is a bioresorbable film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce

Martek Biosciences, a developer of health and wellness products, has reported a net income of $9.6m, or $0.29 per diluted share, for the first quarter of fiscal 2009,

As a result of this sale, Sunesis and SARcode have terminated an earlier licensing agreement relating to this program, and Sunesis will forego future potential milestone payments and

The company raised approximately $15 million through equity contributions by existing investors, including ARCH Venture Partners, HBM BioVentures, Healthcare Focus, Intel Capital, Saudi Venture Development Company, Unilever Technology